19th February 2019 Content supplied by: SeLux Diagnostics, Inc.
Funding for Next Generation High-throughput, Low-cost Same Shift AST
SeLux Diagnostics, Inc., has signed a contract worth up to $45 million, if all contract options are exercised (base award is for $9.3 million), with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR).
SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system.
SeLux NGP is a breakthrough in personalized medicine that will enable the prescription of targeted antibiotic therapies up to 3 days faster than possible with current technologies. This advance offers the promise of improving patient care while simultaneously limiting the medical overreliance on broad-spectrum antibiotics, which fuels the current antibiotic resistance epidemic.
The SeLux NGP Platform
SSeLux NGP determines targeted antibiotic therapies faster and more precisely than possible with today's state-of-the-art techniques. The proprietary Selux technology uniquely provides results 2-5 times faster and for 3-4 times the number of antibiotics than current systems can. Uniquely amongst competitors, SeLux NGP provides the high-throughput, low-cost testing demanded by clinical microbiology laboratories and integrated healthcare systems.
Read 'Microplate-based surface area assay for rapid phenotypic antibiotic susceptibility testing' Scientific Reports volume 9, Article number: 237 (2019)
Date Published: 19th February 2019
Source article link: SeLux Diagnostics, Inc.